AYTU
NASDAQ · Pharmaceuticals
Aytu Biopharma Inc
$2.68
+0.03 (+1.13%)
Financial Highlights (FY 2026)
Revenue
113.02M
Net Income
-23,090,282
Gross Margin
69.0%
Profit Margin
-20.4%
Rev Growth
-11.8%
D/E Ratio
1.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.0% | 69.0% | 29.4% | 29.4% |
| Operating Margin | -11.8% | -10.6% | 29.7% | 36.1% |
| Profit Margin | -20.4% | -19.4% | 29.2% | 27.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 113.02M | 128.13M | 4.25M | 5.07M |
| Gross Profit | 78.03M | 88.46M | 1.25M | 1.49M |
| Operating Income | -13,325,318 | -13,595,721 | 1.26M | 1.83M |
| Net Income | -23,090,282 | -23,558,841 | 1.24M | 1.37M |
| Gross Margin | 69.0% | 69.0% | 29.4% | 29.4% |
| Operating Margin | -11.8% | -10.6% | 29.7% | 36.1% |
| Profit Margin | -20.4% | -19.4% | 29.2% | 27.0% |
| Rev Growth | -11.8% | -11.8% | +20.1% | +11.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 7.44M | 7.44M | 1.90M | 1.72M |
| Total Equity | 6.46M | 6.46M | 20.49M | 17.88M |
| D/E Ratio | 1.15 | 1.15 | 0.09 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -7,055,601 | -7,598,708 | 1.93M | 2.61M |
| Free Cash Flow | — | — | 869.5K | 889.0K |